$Ascendis Pharma A/S(ASND)$ Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026 COPENHAGEN, Denmark, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) notified the Company that information submitted on November 5, 2025, related to the post-marketing requirement, in response to the FDA’s ongoing review of the New Drug Application (NDA) for TransCon CNP (navepegritide) for children with achondroplasia, constituted a major amendment to the NDA. Accordingly, the FDA has extended the PDUFA target action date by three months to February 28, 2026. Fm Yahoo finance
Q: What is Ascendis (ASND) Q2 2025 Earnings Call Transcript Summary?
TigerGPT Answer: Ascendis Pharma A/S (ASND) recently held its Q2 2025 earnings call, providing insights into the company's performance and future outlook. The call highlighted several positive and negative aspects that could influence the company's stock price. Here are the specific viewpoints from the earnings call: Bullish Points: 1. Total product revenue of €153.7 million for Q2 2025, showing substantial sequential growth. 2. TransCon PTH (Europath/Europet) revenue increased to €103 million in Q2 2025, more than double from Q1 2025. 3. Skytrofa FDA approval for adult growth hormone deficiency, supporting future label expansion. 4. TransCon Growth Hormone approved by FDA for adult and pediatric GHD; received MAA in Europe for pediatric GHD. 5. Tran
💰 New Alpha | SPOT/U/PEP Set to Soar in Market Recovery 🚀
💰 U.S. market rebounded while Mag 7 struggled.💹 $Spotify Technology S.A.(SPOT)$ / $Unity Software Inc.(U)$ / $Pepsi(PEP)$: Once oversold due to market sentiment are likely to recover.📣 Stay tuned, supercharge purchasing power through CashBoost!| Market recapOn Monday, all three major U.S. stock indices closed higher, led by gains in the semiconductor sector, while the Mag 7 struggled.$NASDAQ Golden Dragon China Index(HXC)$ increased by over 4%, achieving a closing high not seen in 37 months, with $Alibaba(BABA)$ rising by 4.6% and $XPeng Inc.(XP
Swing Traders' Favorite: Stanley Druckenmiller's 34 New Positions in Q3 2024
The latest 13F filings are out, highlighting the major moves made by top investors in Q3 2024. These reports provide valuable insights into the strategies of the “smart money.” As always, swing traders’ favorite, Stanley Druckenmiller's DUQUESNE FAMILY OFFICE LLC, has unveiled its new positions. Here are the details of the new positions, including ticker, estimated average price, and current market value. PS: Add these to your charting platform's watchlist panel, and you might be able to reverse engineer his selection criteria. $Truist Financial Corp(TFC)$ $40.96 $9.99M $Western Digital(WDC)$ $69.12 $4.88M $Seagate Technology PLC(STX)$ CALL - $28.81M
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.